Gland Pharma confirms compliance with SEBI depository regulations

Gland Pharma (BSE: 543245) has announced its compliance with Regulation 74(5) of the Securities and Exchange Board of India (SEBI) (Depository and Participants) Regulations, 2018. In a filing dated April 10, 2025, Gland Pharma enclosed a confirmation certificate received from its Registrar and Share Transfer Agent, MUFG Intime India Private Limited, which indicates that all securities received for dematerialization during the quarter ending March 31, 2025, were duly processed and confirmed to the depositories. MUFG Intime also verified that security certificates received for dematerialization have been confirmed/rejected and subsequently mutilated and cancelled after verification by the depository participant, with the depositories correctly substituted in the register of members, affirming the company's adherence to regulatory timelines. They also stated that they did not receive any requests for Dematerialization or Rematerialization during this period. This confirmation assures investors that Gland Pharma is committed to maintaining regulatory standards in its handling of securities.